» Articles » PMID: 16690430

Radiation-induced Liver Disease in Three-dimensional Conformal Radiation Therapy for Primary Liver Carcinoma: the Risk Factors and Hepatic Radiation Tolerance

Overview
Specialties Oncology
Radiology
Date 2006 May 13
PMID 16690430
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To identify risk factors relevant to radiation-induced liver disease (RILD) and to determine the hepatic tolerance to radiation.

Methods And Materials: The data of 109 primary liver carcinomas (PLC) treated with hypofractionated three-dimensional conformal radiation therapy (3D-CRT) were analyzed. Seventeen patients were diagnosed with RILD and 13 of 17 died of it.

Results: The risk factors for RILD were late T stage, large gross tumor volume, presence of portal vein thrombosis, association with Child-Pugh Grade B cirrhosis, and acute hepatic toxicity. Multivariate analyses demonstrated that the severity of hepatic cirrhosis was a unique independent predictor. For Child-Pugh Grade A patients, the hepatic radiation tolerance was as follows: (1) Mean dose to normal liver (MDTNL) of 23 Gy was tolerable. (2) For cumulative dose-volume histogram, the tolerable volume percentages would be less than: V5 of 86%, V10 of 68%, V15 of 59%, V20 of 49%, V25 of 35%, V30 of 28%, V35 of 25%, and V40 of 20%. (3) Tolerable MDTNL could be estimated by MDTNL (Gy) = -1.686 + 0.023 * normal liver volume (cm3).

Conclusion: The predominant risk factor for RILD was the severity of hepatic cirrhosis. The hepatic tolerance to radiation could be estimated by dosimetric parameters.

Citing Articles

Navigating the Complexities of Radiation Injuries: Therapeutic Principles and Reconstructive Strategies.

Grosu-Bularda A, Lita F, Hodea F, Bordeanu-Diaconescu E, Cretu A, Dumitru C J Pers Med. 2024; 14(11).

PMID: 39590592 PMC: 11595796. DOI: 10.3390/jpm14111100.


Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage.

Saha B, Pallatt S, Banerjee A, Banerjee A, Pathak R, Pathak S Cells. 2024; 13(18.

PMID: 39329744 PMC: 11429644. DOI: 10.3390/cells13181560.


Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.

Zhang J, Yang Y, Wu Z, Zhang S, Lin Z, Liu H BMJ Open. 2024; 14(6):e077903.

PMID: 38858156 PMC: 11168160. DOI: 10.1136/bmjopen-2023-077903.


Microinvasion in hepatocellular carcinoma: predictive factor and application for definition of clinical target volume for radiotherapy.

Yan H, Liu L, Wang D, Xu J, Sun Y, Liang S World J Surg Oncol. 2024; 22(1):125.

PMID: 38720338 PMC: 11077777. DOI: 10.1186/s12957-024-03399-1.


Predictors of Toxicity in a Randomized Study of Consolidation Chemoradiation Versus Observation After First Line Chemotherapy in Advanced Gall Bladder Cancers.

Agrawal S, Gupta A, Kapoor V, Rahul R, Singh A, Mishra P Adv Radiat Oncol. 2024; 9(5):101468.

PMID: 38590716 PMC: 10999813. DOI: 10.1016/j.adro.2024.101468.